| Clinical effects of recombinant Korean growth hormone (LBD-003). |
|
Duk Hi Kim |
|
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea |
| 국내에서 합성된 성장호르몬 (LBD-003) 의 치료 효과 |
|
김덕희 |
|
연세대학교 의과대학 소아과학교실 |
|
Received: 4 June 1991 • Accepted: 8 July 1991 |
|
|
| Abstract |
|
LBD-003, methionyl GH, has been produced recently in the yeast by the use of recombinant method.
The clinical efficacy and immunogenecity of LBD-003 were studied in 20 patients with naive GH
deficiency.
The subjects of this study were aged 5.1—13.9 years and received GH 1.5IU/kg thrice weekly for
1 year. During treatment, height, body weight & bone age were checked. Blood count, chemistry amd
thyroid hormonal concentrations were checked, measurement of IGF-1 was done before and every 6
month and assay of antibody was performed before, 6 month and 12 month treatment.
The height veloity was increased 8.55±2.28 cm/yr at 6 month & 7.22±1.46 cm/yr from 3.20±l.
21 cm/yr. The ratio of height age and bone age was 1.34 at 6 month and 1.31 at 1 year of therapy.
The plasma IGF-1 levels rose significantly during treatment. No antibody against LBD-003 was
observed in all patients.
Thus, LBD-003 is very effective in stimulating linear growth in hGH deficiency. |
| Key Words:
Short Stature, Growth Hormone Therapy |
|
PDF Links
Download Citation
